Log in

Vanda Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:VNDA)

$15.45
-0.04 (-0.26 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$15.15
Now: $15.45
$15.64
50-Day Range
$12.41
MA: $13.70
$15.48
52-Week Range
$11.83
Now: $15.45
$33.44
Volume448,200 shs
Average Volume553,297 shs
Market Capitalization$824.10 million
P/E Ratio32.19
Dividend YieldN/A
Beta0.29
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$193.12 million
Cash Flow$0.54 per share
Book Value$7.52 per share

Profitability

Net Income$25.20 million

Miscellaneous

Employees270
Market Cap$824.10 million
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.


Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.07 by $1.77. The biopharmaceutical company earned $59.49 million during the quarter, compared to analyst estimates of $58.33 million. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. The firm's revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.13 earnings per share. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Vanda Pharmaceuticals.

What price target have analysts set for VNDA?

8 brokerages have issued 1-year target prices for Vanda Pharmaceuticals' shares. Their forecasts range from $17.00 to $52.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $28.67 in the next year. This suggests a possible upside of 85.5% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

What is the consensus analysts' recommendation for Vanda Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.

What are Wall Street analysts saying about Vanda Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (11/16/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating and $17 target price on VNDA shares as we continue to see limited upside from these levels given a relatively risky pipeline, for which we believe should only be assigned modest value, and a base business that seems more-or-less fully valued. Overall, the quarter looked good with top and bottom line beats driven by Hetlioz and meaningfully lower R&D spend. With that said, 2019 sales guidance for both Hetlioz and Fanapt remain unchanged, though management did update its cash guidance and expects to end 2019 with more cash than previously guided due to the lower spend throughout the year. As we highlighted in our recent deep dive (link here), we see few upside opportunities and more downside risks over the next 12 months and believe the overhang from the FDA lawsuit/tradipitant chronic safety will likely keep shares relatively range bound, in our view." (7/31/2019)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Media headlines about VNDA stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Vanda Pharmaceuticals.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 3,740,000 shares, a drop of 14.4% from the September 30th total of 4,370,000 shares. Based on an average daily trading volume, of 601,000 shares, the short-interest ratio is presently 6.2 days. Currently, 7.2% of the shares of the stock are short sold. View Vanda Pharmaceuticals' Current Options Chain.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include Zogenix (ZGNX), FibroGen (FGEN), Array Biopharma (ARRY), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Sarepta Therapeutics (SRPT) and Nektar Therapeutics (NKTR).

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.47%), Cadence Capital Management LLC (0.32%), Rhumbline Advisers (0.31%), Alberta Investment Management Corp (0.13%), California Public Employees Retirement System (0.13%) and Rice Hall James & Associates LLC (0.11%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which institutional investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, Cadence Capital Management LLC, Mackay Shields LLC and New York State Teachers Retirement System. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Insider Buying and Selling for Vanda Pharmaceuticals.

Which institutional investors are buying Vanda Pharmaceuticals stock?

VNDA stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Alberta Investment Management Corp, Dupont Capital Management Corp, State of Alaska Department of Revenue, California Public Employees Retirement System, Clarus Wealth Advisors, Alps Advisors Inc. and Pacer Advisors Inc.. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $15.45.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $824.10 million and generates $193.12 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  463 (Vote Outperform)
Underperform Votes:  346 (Vote Underperform)
Total Votes:  809
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel